Immunogene therapy using immunomodulating HVJ-E vector augments anti-tumor effects in murine malignant glioma

[1]  X. Zhang,et al.  Adenovirus mediated transfer of p53, GM-CSF and B7-1 suppresses growth and enhances immunogenicity of glioma cells , 2010, Neurological research.

[2]  Y. Kaneda,et al.  Sterile alpha motif containing domain 9 is involved in death signaling of malignant glioma treated with inactivated Sendai virus particle (HVJ‐E) or type I interferon , 2010, International journal of cancer.

[3]  Y. Kaneda,et al.  Highly efficient eradication of intracranial glioblastoma using Eg5 siRNA combined with HVJ envelope , 2009, Gene Therapy.

[4]  Y. Kaneda,et al.  Efficient eradication of hormone‐resistant human prostate cancers by inactivated Sendai virus particle , 2009, International journal of cancer.

[5]  鈴木 勇人.  Sendai virus F glycoprotein induces IL-6 production in dendritic cells in a fusion-independent manner , 2009 .

[6]  M. Sena-Esteves,et al.  Controlling brain tumor growth by intraventricular administration of an AAV vector encoding IFN-β , 2009, Cancer Gene Therapy.

[7]  D. Vignali,et al.  How regulatory T cells work , 2008, Nature Reviews Immunology.

[8]  Y. Kaneda,et al.  New potential therapy for orthotopic bladder carcinoma by combining HVJ envelope with doxorubicin , 2008, Cancer Chemotherapy and Pharmacology.

[9]  A. Sonabend,et al.  The role of regulatory T cells in malignant glioma. , 2008, Anticancer research.

[10]  Y. Kaneda,et al.  A new therapy for highly effective tumor eradication using HVJ-E combined with chemotherapy , 2007, BMC medicine.

[11]  L. Boon,et al.  CD4+FoxP3+ regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responses in vivo , 2007, International journal of cancer.

[12]  M. Lesniak,et al.  Prolongation of survival following depletion of CD4+CD25+ regulatory T cells in mice with experimental brain tumors. , 2006, Journal of neurosurgery.

[13]  M. Lesniak,et al.  An increase in CD4+CD25+FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme. , 2006, Neuro-oncology.

[14]  Yasuhiko Tabata,et al.  Targeted chemotherapy against intraperitoneally disseminated colon carcinoma using a cationized gelatin–conjugated HVJ envelope vector , 2006, Molecular Cancer Therapeutics.

[15]  D. Bigner,et al.  Recent advances in the treatment of malignant astrocytoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  G. Palù,et al.  Combined HSV-TK/IL-2 gene therapy in patients with recurrent glioblastoma multiforme: biological and clinical results , 2005, Cancer Gene Therapy.

[17]  Yasufumi Kaneda,et al.  Rad51 siRNA delivered by HVJ envelope vector enhances the anti‐cancer effect of cisplatin , 2005, The journal of gene medicine.

[18]  J. Markert,et al.  Increased efficacy of an interleukin-12-secreting herpes simplex virus in a syngeneic intracranial murine glioma model. , 2005, Neuro-oncology.

[19]  Y. Iwadate,et al.  Recombinant Sendai Virus Vector Induces Complete Remission of Established Brain Tumors through Efficient Interleukin-2 Gene Transfer in Vaccinated Rats , 2005, Clinical Cancer Research.

[20]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[21]  T. Malek,et al.  Tolerance, not immunity, crucially depends on IL-2 , 2004, Nature Reviews Immunology.

[22]  H. Tsuda,et al.  Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model , 2004, Gene Therapy.

[23]  Y. Kaneda.  New vector innovation for drug delivery: development of fusigenic non-viral particles. , 2003, Current drug targets.

[24]  A. Sloan,et al.  Relative survival rates and patterns of diagnosis analyzed by time period for individuals with primary malignant brain tumor, 1973-1997. , 2003, Journal of neurosurgery.

[25]  R. Ransohoff,et al.  Three or more routes for leukocyte migration into the central nervous system , 2003, Nature Reviews Immunology.

[26]  K. Lillehei,et al.  Cell-mediated immunotherapy: a new approach to the treatment of malignant glioma. , 2003, Cancer control : journal of the Moffitt Cancer Center.

[27]  Ruslan Medzhitov,et al.  Toll Pathway-Dependent Blockade of CD4+CD25+ T Cell-Mediated Suppression by Dendritic Cells , 2003, Science.

[28]  G. Tomei,et al.  Suppression of malignant glioma recurrence in a newly developed animal model by endogenous inhibitors. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[29]  J. Lafaille,et al.  Interleukin 2 Signaling Is Required for CD4+ Regulatory T Cell Function , 2002, The Journal of experimental medicine.

[30]  Tomoyuki Nishikawa,et al.  Hemagglutinating virus of Japan (HVJ) envelope vector as a versatile gene delivery system. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[31]  J. Brotchi,et al.  Granulocyte macrophage-colony stimulating factor gene transfer to induce a protective anti-tumoral immune response against the 9L rat gliosarcoma model. , 2002, International Journal of Oncology.

[32]  K. Ikenaka,et al.  Eradication of murine brain tumors by direct inoculation of concentrated high titer-recombinant retrovirus harboring the herpes simplex virus thymidine kinase gene , 2001, Gene Therapy.

[33]  Foss,et al.  In Vitro and In Vivo Bioactivity of Single‐Chain Interleukin‐12 , 1999, Scandinavian journal of immunology.

[34]  E. Cohen,et al.  Prolongation of survival of mice with glioma treated with semiallogeneic fibroblasts secreting interleukin-2. , 1999, Neurosurgery.

[35]  M. Mizuno,et al.  Antitumor effect and cellular immunity activation by murine interferon-β gene transfer against intracerebral glioma in mouse , 1999, Gene Therapy.

[36]  K. Frei,et al.  Antigen presentation in the CNS , 1997, Molecular Psychiatry.

[37]  P. Shrikant,et al.  The central nervous system as an immunocompetent organ: role of glial cells in antigen presentation. , 1996, Journal of immunology.

[38]  M. Hart,et al.  Nervous tissue as an immune compartment: the dialect of the immune response in the CNS. , 1994, Immunology today.

[39]  Z. Ram,et al.  In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. , 1992, Science.

[40]  S. Rosenberg,et al.  NIH conference. New approaches to the immunotherapy of cancer using interleukin-2. , 1988, Annals of internal medicine.

[41]  C. Dunnett.  A Multiple Comparison Procedure for Comparing Several Treatments with a Control , 1955 .

[42]  P. Medawar.  Immunity to homologous grafted skin; the fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye. , 1948, British journal of experimental pathology.

[43]  A. Liston,et al.  Regulatory T Cells , 2011, Methods in Molecular Biology.

[44]  Y. Kaneda,et al.  Inactivated Sendai virus particles eradicate tumors by inducing immune responses through blocking regulatory T cells. , 2007, Cancer research.

[45]  Y. Kaneda,et al.  Intratumoral injection of inactivated Sendai virus particles elicits strong antitumor activity by enhancing local CXCL10 expression and systemic NK cell activation , 2007, Cancer Immunology, Immunotherapy.

[46]  Y. Kaneda,et al.  Development of HVJ Envelope Vector and Its Application to Gene Therapy. , 2005, Advances in genetics.

[47]  Yunhui Liu,et al.  In situ adenoviral interleukin 12 gene transfer confers potent and long-lasting cytotoxic immunity in glioma , 2002, Cancer Gene Therapy.

[48]  R. Mulligan,et al.  Bioactive murine and human interleukin-12 fusion proteins which retain antitumor activity in vivo , 1997, Nature Biotechnology.

[49]  D. Pardoll.  Paracrine cytokine adjuvants in cancer immunotherapy. , 1995, Annual review of immunology.

[50]  P. Jenkins,et al.  Hip complications following chemoradiotherapy. , 1995, Clinical oncology (Royal College of Radiologists (Great Britain)).

[51]  P. Clifford,et al.  The Ommaya reservoir in chemotherapy for malignant disease in the CNS. , 1981, Clinical oncology.